CU
Uppugunduri Satyanarayana, Chakradhara Rao
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients | Therapeutic drug monitoring |  | 2024 | 8 | 5 | ||
| Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines : The need of the hour | The Indian journal of pharmacology | | 2024 | 7 | 5 | ||
| The Role of Genomics in Reshaping Healthcare Delivery : Personalized Medicine | The National Medical Journal of India | | 2024 | 11 | 13 | ||
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy | Clinical pharmacology & therapeutics | | 2024 | 9 | 6 | ||
| In vitro screening of UGT2B10 in silico prioritized putative ligands from drugs used in the pediatric hematopoietic stem cell transplantation setting | Pharmacology research & perspectives | | 2024 | 77 | 50 | ||
| A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions : a reality for future health care | Pharmacogenomics journal | | 2024 | 52 | 40 | ||
| Impact of Genetic Variants on Postoperative Pain and Fentanyl Dose Requirement in Patients Undergoing Major Breast Surgery: A Candidate Gene Association Study | Anesthesia & analgesia |  | 2023 | 66 | 0 | ||
| Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report | Pharmacogenomics | | 2023 | 53 | 67 | ||
| Clinical Pharmacology and Pharmacogenomics for Implementation of Personalized Medicine | Pharmacogenomics | | 2023 | 20 | 53 | ||
| Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan | Bone marrow transplantation | | 2023 | 9 | 5 | ||
| Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT | Transplantation and cellular therapy | | 2023 | 85 | 85 | ||
| Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response | Pharmaceuticals | | 2022 | 81 | 20 | ||
| A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation | BMC molecular and cell biology | | 2022 | 71 | 68 | ||
| Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol | BMJ open | | 2022 | 61 | 51 | ||
| Prioritization of microRNA biomarkers for a prospective evaluation in a cohort of myocardial infarction patients based on their mechanistic role using public datasets | Frontiers in cardiovascular medicine | | 2022 | 94 | 85 | ||
| GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation | Journal of cancer research and clinical oncology | | 2022 | 380 | 172 | ||
| Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT | Bone marrow transplantation | | 2021 | 273 | 2 | ||
| Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience | British journal of haematology | | 2021 | 230 | 0 | ||
| Indo-Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine | Pharmacogenomics | | 2021 | 276 | 0 | ||
| Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors | Frontiers in pharmacology | | 2021 | 65 | 139 | ||
| Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review | European journal of clinical pharmacology | | 2021 | 311 | 194 | ||
| The Catalytic Activity of GSTM1 In vitro is Independent of MAPK8 | Drug metabolism letters | | 2021 | 98 | 62 | ||
| In silico and in vitro investigations on the protein–protein interactions of glutathione S-transferases with mitogen-activated protein kinase 8 and apoptosis signal-regulating kinase 1 | Journal of Biomolecular Structure and Dynamics | | 2021 | 290 | 208 | ||
| Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study | CPT: pharmacometrics & systems pharmacology | | 2021 | 243 | 126 | ||
| Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases | Journal of Visualized Experiments | | 2020 | 350 | 711 | ||
| Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation | Biology of Blood and Marrow Transplantation | | 2020 | 338 | 0 | ||
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing | Clinical Pharmacology and Therapeutics | | 2020 | 290 | 0 | ||
| Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children | Therapeutic Drug Monitoring | | 2020 | 448 | 167 | ||
| Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia | Genes | | 2020 | 255 | 157 | ||
| Neuroprotective agents in Acute Ischemic Stroke-A Reality Check | Biomedicine & Pharmacotherapy | | 2019 | 275 | 286 | ||
| Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation | British Journal of Clinical Pharmacology | | 2018 | 371 | 146 | ||
| Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation | The Pharmacogenomics Journal | | 2018 | 522 | 225 | ||
| Frequency of chemotherapy medication errors: A systematic review | Journal of Pharmacology and Pharmacotherapeutics | | 2018 | 662 | 491 | ||
| Development and validation of an allele-specific PCR assay for genotyping a promoter and exonic single nucleotide polymorphisms of MGMT gene | Journal of Biological Methods | | 2018 | 317 | 148 | ||
| Developmental Pattern of Hepatic Drug‑Metabolizing Enzymes in Pediatric Population and its Role in Optimal Drug Treatment | Archives of Medicine and Health Sciences | | 2017 | 361 | 509 | ||
| GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation | Biology of Blood and Marrow Transplantation | | 2017 | 490 | 17 | ||
| GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study | Oncotarget | | 2017 | 551 | 242 | ||
| Potential Predictive Biomarkers used to optimize treatments for Sinusoidal Obstruction Syndrome in pediatric Hematopoietic stem cell transplantation | Bulletin suisse du cancer | | 2016 | 448 | 1,779 | ||
| Commentary: A myriad aberrations on information of ontogeny of drug metabolizing enzymes in the pediatric population: an obstacle for personalizing drug therapy in the pediatric population | Drug metabolism letters | | 2016 | 588 | 249 | ||
| Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine | Journal of Cardiovascular Pharmacology | | 2016 | 456 | 0 | ||
| Detection of busulfan adducts on proteins | RCM. Rapid communications in mass spectrometry | | 2016 | 659 | 190 | ||
| Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use | International Journal of Molecular Sciences | | 2016 | 581 | 428 | ||
| Severe Vincristine-Induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study | Clinical therapeutics | | 2016 | 554 | 2 | ||
| The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation | Pharmacogenomics journal | | 2014 | 733 | 8 | ||
| Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children | Current drug metabolism | | 2014 | 534 | 9 | ||
| The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children | PloS one | | 2013 | 721 | 385 | ||
| Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma | Virology journal | | 2013 | 653 | 188 | ||
| Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients | Bone marrow transplantation | | 2013 | 654 | 5 | ||
| Transcriptional regulation of CYP2C19 and its role in altered enzyme activity | Current drug metabolism | | 2012 | 601 | 0 | ||
| A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry | Analytical & bioanalytical chemistry | | 2012 | 658 | 301 | ||
| A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry | RCM. Rapid communications in mass spectrometry | | 2012 | 841 | 831 | ||
| Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia | European journal of clinical pharmacology | | 2012 | 598 | 272 |
